Skip to content
Peptide Atlas
All goals

Peptides studied for firmer skin and fewer lines

For the skin side of this goal, several of these compounds act on the same target: the collagen and support proteins beneath the skin's surface. The strongest evidence is for topical matrikine peptides — Matrixyl and Palmitoyl Tripeptide-1 — where small human trials report modest reductions in wrinkles and gains in firmness. The rest rest on laboratory, animal, or blend-level reasoning. The library does not yet speak to hair shaft (keratin) or nails.

The biology of this goal

Below the surface, skin is held up by a mesh of support proteins. The main one is collagen, which gives skin its structure and firmness; elastin lets it spring back, and other filler molecules keep it plump. Cells called fibroblasts build and maintain this mesh. As skin ages, the mesh thins, breaks down faster than it is rebuilt, and lines and slackness appear. Several of the peptides here are messenger molecules that tell fibroblasts to make more collagen, or that slow the breakdown of what is already there.

What the research supports

6 of 7 relevant, from 10 considered

PTD-DBM

Tier 3 · Reported use

Animal and laboratory studies suggest PTD-DBM can activate β-catenin and increase collagen production, but the work is in cultured cells and mice.

PTD-DBM is a lab-made peptide designed to release a natural brake on a growth pathway inside skin and follicle cells. That pathway, called Wnt/β-catenin, drives tissue building; a protein called CXXC5 normally holds it in check. By blocking CXXC5, PTD-DBM is described as freeing that pathway to turn up collagen production.

  • Overexpression and silencing of CXXC5 in cultured cells differentially regulated β-catenin, α-smooth muscle actin, and collagen I, pointing to a role in myofibroblast differentiation and collagen production.1

  • In lab studies PTD-DBM disrupted the CXXC5–Dvl negative feedback loop and activated β-catenin and collagen production.1

  • Mice lacking CXXC5 showed enhanced keratin 14 and collagen synthesis.1

  • Combined with valproic acid, a Wnt/β-catenin activator, PTD-DBM synergistically accelerated skin wound healing in mice.1

  • CXXC5 acts as a negative regulator of the Wnt/β-catenin pathway involved in tissue regeneration and wound healing.2

What this doesn't establish

There are no human trials showing PTD-DBM firms skin or reduces wrinkles, and the collagen findings come from wound-healing and cell models rather than cosmetic-aging endpoints.

Matrixyl

Tier 2 · Preclinical

Human trials report that topical Pal-KTTKS produced measurable, modest reductions in fine lines and wrinkles with good tolerability.

Matrixyl is the trade name for a small peptide (Pal-KTTKS) built from a fragment of collagen with a fatty tail attached. It acts as a false alarm: it signals fibroblasts that collagen has been damaged, prompting them to build more. The fatty tail helps the peptide slip through the skin's oily outer barrier to reach the deeper layers where fibroblasts live.

  • In a 12-week, double-blind, placebo-controlled, split-face trial of 93 women aged 35–55, 3 ppm Pal-KTTKS significantly improved wrinkle/fine-line reduction versus placebo by both quantitative technical analysis and expert grader image analysis, and was well tolerated.4

  • The peptide stimulated collagen production in human dermal fibroblasts at low concentration (0.0062 wt%).5

  • In hairless mouse skin, palmitoylation gave Pal-KTTKS greater stability and permeability than unmodified KTTKS; Pal-KTTKS reached all skin layers (about 0.3 μg/cm² in the dermis) while KTTKS was undetectable in any layer.6

What this doesn't establish

The clinical improvements were modest and measured over 12 weeks in one population; permeation data show only a small fraction of applied peptide reaches the dermis.

GHK-Cu

Tier 2 · Preclinical

Animal and laboratory studies suggest GHK-Cu increases matrix protein synthesis and improves skin firmness and elasticity, and reviews note a striking absence of clinical trials of the copper complex itself.

GHK-Cu is a naturally occurring three-amino-acid peptide bound to a copper atom. Found in human blood and released when tissue is injured, it delivers copper to skin cells and signals them to make more collagen, elastin, and plumping molecules while calming inflammation. Its natural levels fall with age.

  • GHK increases collagen, elastin, and glycosaminoglycan synthesis and its tissue-repair action has been demonstrated across skin and several other tissues.7,8

  • Because GHK is fairly hydrophilic and permeates the stratum corneum poorly, delivery aids such as cell-penetrating peptides, microneedles and liposomes are being explored.8,9

What this doesn't establish

Much of the supporting review literature is authored by parties associated with the compound, and there is a noted lack of controlled human trials on GHK-Cu delivery and efficacy.

Palmitoyl Tripeptide-1

Tier 2 · Preclinical

Human trial data report that a timed nighttime regimen of Palmitoyl Tripeptide-1 improved skin firmness and other quality measures.

Palmitoyl Tripeptide-1 (Pal-GHK) is the same small GHK collagen fragment as GHK-Cu but without copper, carrying a fatty tail for skin penetration. It acts as a messenger telling fibroblasts to make new collagen. Unlike GHK-Cu, it does not deliver copper ions.

  • In a circadian-synchronized fibroblast model, PT-1 boosted nighttime collagen synthesis.10

  • In an 8-week clinical trial of 30 women, a timed regimen of nighttime PT-1 with daytime baicalin significantly improved skin luminance (+16.29%), nasolabial fold depth (−36.35%) and firmness (R2 +24.35%), with increased collagen fiber density seen in mice.10

  • The GHK sequence is a fragment of type I collagen, and Palmitoyl Tripeptide-1 functions primarily as a skin-conditioning agent in cosmetics.12

  • GHK has tissue-regeneration capability and enhances collagen and glycosaminoglycan synthesis, with properties relevant to wrinkle prevention/reduction.11

What this doesn't establish

The clinical result was in only 30 participants and used PT-1 combined with daytime baicalin on a circadian schedule, so the peptide's independent effect cannot be isolated.

GLOW

Tier 3 · Reported use

Human-tier review data support the GHK component's collagen and skin effects, but there is no study of the GLOW blend itself, and injectable peptide use carries documented practical risks.

GLOW is not one drug but a marketed blend of three separately studied peptides — GHK-Cu, BPC-157 and TB-500 — sold for skin quality and recovery. The skin rationale rests on the GHK-Cu component, which signals fibroblasts to build collagen and other matrix. The claimed advantage of combining the three is based on reasoning and practitioner reports, not on any study of the blend itself.

  • GHK increases collagen, elastin, and glycosaminoglycan synthesis, and its tissue-repair action is documented across skin and other tissues.13,14

  • Community and clinical commentary note that unregulated peptide injections may cause injection-site skin reactions such as redness, pain, swelling or skin changes, and often bypass FDA review.15

What this doesn't establish

No evidence tests the three-peptide blend together; combination benefit is theoretical, and the supporting skin claims are entirely attributable to GHK-Cu alone.

Palmitoyl Tetrapeptide-7

Tier 3 · Reported use

Human-tier safety review classifies it as a skin-conditioning agent, and laboratory and review data suggest anti-aging and matrix-protective effects, but direct clinical efficacy data are limited.

Palmitoyl Tetrapeptide-7 is a lab-made four-amino-acid peptide with a fatty tail for skin penetration. Rather than building collagen directly, its main reported job is to calm the low-grade inflammation in skin that tends to rise with age and sun exposure. By quieting that inflammatory signal, it is thought to help protect the existing support mesh from breaking down. It is best known as one of the two active peptides in the Matrixyl 3000 blend.

  • Palmitoyl Tetrapeptide-7 functions primarily as a skin-conditioning agent in cosmetics at typical use concentrations under 10 ppm.17,18

  • A review of anti-aging peptides for skincare reports that peptides including Palmitoyl Tetrapeptide-7 can improve skin appearance and elasticity, and that nanodelivery systems can increase their safety and bioactivity.16

What this doesn't establish

The available sources establish its cosmetic role and safety, not a measured, controlled effect on wrinkles or firmness on its own.

How they work together

Check this stack

Several of these compounds are described as complementary rather than redundant because they act on different points of the same collagen balance. Matrixyl and Palmitoyl Tripeptide-1 are both palmitoylated matrikines that drive fibroblasts to build collagen through somewhat different routes, so they are frequently layered and considered additive. Palmitoyl Tetrapeptide-7 pairs with either of them as the classic 'Matrixyl 3000' logic — one side builds new matrix while the other calms inflammation and protects existing matrix from breakdown. PTD-DBM builds collagen through Wnt/β-catenin, a different upstream signal from the matrikine peptides, making it a plausible non-redundant partner for both Matrixyl and GHK-Cu; GHK-Cu and PTD-DBM are noted as converging on collagen and dermal-matrix building by different routes. GHK-Cu has no documented pairing data with the Matrixyl-family peptides in this library. It is worth stressing these relationships are mechanistic reasoning and formulation convention; none rests on a head-to-head study of the combinations for skin firmness.

  • BPC-157 + GHK-Cu

    May be complementary

    Both peptides promote wound healing, collagen synthesis and angiogenesis through overlapping PI3K/Akt, mTOR, TGF-β and AMPK signaling, but via distinct entry points: BPC-157 through VEGFR2/eNOS and growth-factor induction, GHK-Cu through copper delivery, lysyl-oxidase-driven collagen/elastin crosslinking and Nrf2 antioxidant activation. They are frequently combined for skin/connective-tissue remodeling.

  • BPC-157 + TB-500

    May be complementary

    BPC-157 and TB-500 drive tissue repair through entirely different molecular targets (VEGF/NO signalling vs. actin regulation), so they are frequently discussed as a complementary healing pair rather than a redundant one.

  • GHK-Cu + PTD-DBM

    May be complementary

    Both peptides converge on hair-follicle activation and collagen/dermal-matrix building, but by different routes: PTD-DBM releases the CXXC5 brake to boost Wnt/beta-catenin signaling in follicle cells, while GHK-Cu delivers copper to collagen/elastin-building enzymes and has its own Wnt/beta-catenin hair-growth activity. Used together (typically topically) they can reinforce hair regrowth and skin/collagen quality through non-redundant mechanisms.

  • GHK-Cu + TB-500

    May be complementary

    GHK-Cu stimulates collagen/GAG synthesis and ECM remodeling while TB-500 (Thymosin β4 fragment) sequesters G-actin to promote cell migration, angiogenesis and inflammation resolution. Different mechanisms both converge on angiogenesis, integrin/ECM remodeling and NF-κB suppression — a classic complementary regeneration pairing.

  • Matrixyl + Palmitoyl Tetrapeptide-7

    May be complementary

    These two work as a classic cosmetic pair: Matrixyl actively builds new collagen and matrix, while Palmitoyl Tetrapeptide-7 calms inflammatory cytokines (IL-6, IL-1β) and protects the existing matrix from MMP-driven breakdown. One adds new material, the other prevents its degradation, so combining them addresses both sides of the collagen balance in aging skin.

  • Matrixyl + Palmitoyl Tripeptide-1

    May be complementary

    Both are palmitoylated matrikine peptides that drive fibroblasts to make more collagen and rebuild the dermal matrix, but they come from different collagen fragments and hit the pathway somewhat differently (Matrixyl/Pal-KTTKS via a fibroblast matrikine/TGF-beta route; Pal-GHK via broad gene modulation and MMP suppression). Because they converge on the same skin-firming, wrinkle-reducing outcome through non-identical routes, they are frequently layered together in topical formulas and are considered additive rather than redundant.

  • Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1

    May be complementary

    These two are the classic 'Matrixyl 3000' pairing in cosmetic formulations. Palmitoyl Tripeptide-1 (Pal-GHK) is a matrikine that actively drives fibroblasts to build new collagen, elastin and glycosaminoglycans, while Palmitoyl Tetrapeptide-7 works from the other direction — calming inflammatory cytokines (IL-6, IL-1β) and protecting the existing matrix from MMP-driven breakdown. Building plus protecting is exactly the kind of different-mechanism convergence that makes them a well-established, synergistic skin-firmness combination.

  • BPC-157 + PTD-DBM

    No known conflict in the research

    BPC-157 drives angiogenesis, fibroblast activation and collagen deposition through VEGFR2/eNOS and FAK-paxillin signaling, while PTD-DBM boosts collagen and wound repair via Wnt/beta-catenin. Different upstream targets both converging on faster wound healing and matrix formation make this a complementary repair combination.

  • Matrixyl + PTD-DBM

    No known conflict in the research

    PTD-DBM drives collagen (including collagen III) via Wnt/beta-catenin activation in dermal cells, while Matrixyl (Pal-KTTKS) is a matrikine that signals fibroblasts through MAPK/ERK to make collagen I, III and IV. They stimulate collagen by different upstream signals, so pairing them for skin firmness is a plausible non-redundant combination.

  • Matrixyl + TB-500

    No known conflict in the research

    TB-500 supports the cell-migration and ECM-remodeling side of repair, while Matrixyl (a topical collagen matrikine) stimulates collagen I/III/IV and fibronectin production. They target different steps of matrix rebuilding \u2014 one systemic, one topical \u2014 so they complement rather than overlap.

  • Palmitoyl Tetrapeptide-7 + PTD-DBM

    No known conflict in the research

    Palmitoyl Tetrapeptide-7 protects the extracellular matrix by damping inflammatory cytokines (IL-6, IL-1beta) and inhibiting MMP degradation, while PTD-DBM actively builds collagen/dermal matrix via Wnt/beta-catenin. One reduces breakdown while the other increases production, a complementary approach to skin quality.

  • Palmitoyl Tripeptide-1 + PTD-DBM

    No known conflict in the research

    Palmitoyl Tripeptide-1 (Pal-GHK) stimulates collagen and elastin through TGF-beta/Smad matrikine signaling, whereas PTD-DBM works through Wnt/beta-catenin. Both feed the same goal of dermal-matrix rebuilding through different pathways, making them a reasonable complementary skin/collagen pairing.

  • Palmitoyl Tripeptide-1 + TB-500

    No known conflict in the research

    TB-500 (thymosin β4 fragment) promotes cell migration, angiogenesis and anti-inflammatory tissue repair, while Pal-GHK drives collagen and matrix deposition. They converge on the same goal of tissue healing through distinct pathways (actin/cytoskeletal remodeling vs TGF-β collagen synthesis), so they can be viewed as complementary for repair contexts.

  • PTD-DBM + TB-500

    No known conflict in the research

    PTD-DBM accelerates wound healing and collagen deposition through Wnt/beta-catenin, while TB-500 promotes cell migration, angiogenesis and matrix remodeling via actin regulation (and also touches Wnt/beta-catenin). The two support tissue and wound repair through largely different mechanisms, a plausible complementary pairing.

7 other pairings have no documented interaction in our data — that is not a safety clearance.
  • BPC-157 + Matrixyl
  • BPC-157 + Palmitoyl Tetrapeptide-7
  • BPC-157 + Palmitoyl Tripeptide-1
  • GHK-Cu + Matrixyl
  • GHK-Cu + Palmitoyl Tetrapeptide-7
  • GHK-Cu + Palmitoyl Tripeptide-1
  • Palmitoyl Tetrapeptide-7 + TB-500

Compounds we looked at and left out

These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.

  • Argirelinematched on collagen production

    Argireline is linked to collagen production, but in this compound that activity is about wrinkle reduction through reduced muscle contraction.

    “By imitating this fragment, it is proposed to interfere with the machinery nerves use to release the chemical messenger (acetylcholine) that tells facial muscles to contract.”— from its own profile
  • Elafinmatched on skin structure (dermal matrix)

    Elafin is linked to skin structure (dermal matrix), but in this compound that activity is about inflammatory response and immune defense in diseased skin.

    “Elafin is an epithelial host-defense protein that is absent in normal skin but highly expressed in inflamed skin keratinocytes”— from its own profile
  • Leuphasylmatched on skin structure (dermal matrix)

    Leuphasyl is linked to skin structure (dermal matrix), but in this compound that activity is about muscle relaxation and wrinkle reduction through neuromuscular inhibition.

    “it is reported to bind enkephalin/opioid receptors on the nerve side of the neuromuscular junction and dampen the release of acetylcholine, the signal that makes facial muscles contract”— from its own profile

What we can't tell you yet

This library addresses only the skin side of the goal — collagen and the dermal support matrix. It has no compound linked to keratin or the hair shaft, and nothing here speaks to nails. PTD-DBM's hair-follicle findings come entirely from mice and cultured cells, not people.

  • No compound in our library is currently linked to keratin and the hair shaft.

Sources

Ordered as cited above.

  1. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  2. PTD-DBM - Wikipedia(opens in a new tab)
    Tier 2Web · en.wikipedia.org
  3. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  4. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  5. Nanostructure and Collagen-Stimulating Activity of Cationic Pentapeptide Lipopeptides.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  6. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  7. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data(opens in a new tab)
    Tier 2Web · mdpi.com
  8. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  9. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  10. Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  11. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  12. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics(opens in a new tab)
    Tier 1Web · cir-safety.org
  13. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  14. Regenerative and Protective Actions of the GHK-Cu Peptide in ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  15. 4 Dangerous Side Effects of Peptide Injections(opens in a new tab)
    Tier 3Web · verywellhealth.com
  16. Anti-aging peptides for advanced skincare: Focus on nanodelivery systems(opens in a new tab)
    Tier 2Web · sciencedirect.com
  17. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics(opens in a new tab)
    Tier 1Web · journals.sagepub.com
  18. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics(opens in a new tab)
    Tier 3Web · cir-safety.org

This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.

See something wrong or out of date on this page? Report it.